Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous GLP-1 versus insulin for glycaemic control in critically ill patients
ACTRN12613001383752Phase 3Withdrawn
- Sponsor
- Dr Yasmine Ali Abdelhamid
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Glucagon-like peptide 1 and human insulin in Stress Hyperglycemia (SH) and critical illness (2 arms), sponsored by Dr Yasmine Ali Abdelhamid. Primary endpoint: Glycaemic control. Planned start Mar 2016; status: withdrawn.
02
Drugs
Glucagon-like peptide 1human insulin
03
Conditions
Stress Hyperglycemia (SH)critical illness
Beyond the preview
Go deeper on ACTRN12613001383752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001383752.